Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection

Yeni, 2002, Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel., JAMA, 288, 222, 10.1001/jama.288.2.222

Berger, 1999, Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease., Annu Rev Immunol, 17, 657, 10.1146/annurev.immunol.17.1.657

Kilby, 1998, Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry., Nat Med, 4, 1302, 10.1038/3293

Lalezari, 2003, A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults., Antivir Ther, 8, 279, 10.1177/135965350300800403

Lalezari, 2003, Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America., N Engl J Med, 348, 2175, 10.1056/NEJMoa035026

Hatse, 2002, Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4., FEBS Lett, 527, 255, 10.1016/S0014-5793(02)03143-5

Gerlach, 2001, Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor., J Biol Chem, 276, 14153, 10.1074/jbc.M010429200

Schols, 1997, Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4., J Exp Med, 186, 1383, 10.1084/jem.186.8.1383

Dragic, 1996, HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5., Nature, 381, 667, 10.1038/381667a0

Deng, 1996, Identification of a major co-receptor for primary isolates of HIV-1., Nature, 381, 661, 10.1038/381661a0

Alkhatib, 1996, CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1., Science, 272, 1955, 10.1126/science.272.5270.1955

Connor, 1994, Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression., J Virol, 68, 4400, 10.1128/JVI.68.7.4400-4408.1994

Tersmette, 1988, Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex., J Virol, 62, 2026, 10.1128/JVI.62.6.2026-2032.1988

Schuitemaker, 1992, Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population., J Virol, 66, 1354, 10.1128/JVI.66.3.1354-1360.1992

Simmons, 1996, Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry., J Virol, 70, 8355, 10.1128/JVI.70.12.8355-8360.1996

Zaitseva, 1997, Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection., Nat Med, 3, 1369, 10.1038/nm1297-1369

Michael, 1998, Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32., J Virol, 72, 6040, 10.1128/JVI.72.7.6040-6047.1998

Fenyo, 1988, Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates., J Virol, 62, 4414, 10.1128/JVI.62.11.4414-4419.1988

Donzella, 1998, AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor., Nat Med, 4, 72, 10.1038/nm0198-072

De Clercq, 1994, Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100., Antimicrob Agents Chemother, 38, 668, 10.1128/AAC.38.4.668

Harouse, 2003, CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques., Proc Natl Acad Sci USA, 100, 10977, 10.1073/pnas.1933268100

Datema, 1996, Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry., Antimicrob Agents Chemother, 40, 750, 10.1128/AAC.40.3.750

Hendrix, 2000, Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers., Antimicrob Agents Chemother, 44, 1667, 10.1128/AAC.44.6.1667-1673.2000

Bjorndal, 1997, Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype., J Virol, 71, 7478, 10.1128/JVI.71.10.7478-7487.1997

Liles, 2003, Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist., Blood, 102, 2728, 10.1182/blood-2003-02-0663

Vandamme, 1996, Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test., J Acquir Immune Defic Syndr Hum Retrovirol, 13, 127, 10.1097/00042560-199610010-00003

Petropoulos, 2000, A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1., Antimicrob Agents Chemother, 44, 920, 10.1128/AAC.44.4.920-928.2000

Veazey, 2003, Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection., J Exp Med, 198, 1551, 10.1084/jem.20031266

Hatse, 2001, Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100., Mol Pharmacol, 60, 164, 10.1124/mol.60.1.164

Palani, 2001, Discovery of 4-[(Z)-(4-bromophenyl)-(ethoxyimino)methyl]-1-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4-methyl-1,4-bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection., J Med Chem, 44, 3339, 10.1021/jm015526o

Strizki, 2001, SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo., Proc Natl Acad Sci USA, 98, 12718, 10.1073/pnas.221375398

Tsamis, 2003, Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry., J Virol, 77, 5201, 10.1128/JVI.77.9.5201-5208.2003

Labrosse, 1998, Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100., J Virol, 72, 6381, 10.1128/JVI.72.8.6381-6388.1998

Hatse, 2003, Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry., FEBS Lett, 546, 300, 10.1016/S0014-5793(03)00609-4

Brandt, 2002, Association of chemokine-mediated block to HIV entry with coreceptor internalization., J Biol Chem, 277, 17291, 10.1074/jbc.M108232200

Soriano, 2002, Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression., J Infect Dis, 186, 922, 10.1086/343741

Derdeyn, 1999, Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals., AIDS Res Hum Retroviruses, 15, 1063, 10.1089/088922299310359

Connor, 1997, Change in coreceptor use correlates with disease progression in HIV-1-infected individuals., J Exp Med, 185, 621, 10.1084/jem.185.4.621

Scarlatti, 1997, In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression., Nat Med, 3, 1259, 10.1038/nm1197-1259

Schramm, 2000, Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease., J Virol, 74, 184, 10.1128/JVI.74.1.184-192.2000

Malkevitch, 2001, Coreceptor choice and T cell depletion by R5, X4, and R5X4 HIV-1 variants in CCR5-deficient (CCR5delta32) and normal human lymphoid tissue., Virology, 281, 239, 10.1006/viro.2000.0807

Tersmette, 1989, Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates., J Virol, 63, 2118, 10.1128/JVI.63.5.2118-2125.1989

Doranz, 2001, Safe use of the CXCR4 inhibitor ALX40-4C in humans., AIDS Res Hum Retroviruses, 17, 475, 10.1089/08892220151126508